{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:33Z","timestamp":1790332353660,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fogarty International Center of the National Institutes of Health","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}]},{"name":"Fogarty International Center of the National Institutes of Health","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}]},{"name":"Fogarty International Center of the National Institutes of Health","award":["D43TW009771"],"award-info":[{"award-number":["D43TW009771"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00800-1","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:23:40Z","timestamp":1758882220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dolutegravir-associated hyperglycemia: a narrative review"],"prefix":"10.1186","volume":"22","author":[{"given":"Allan","family":"Buzibye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ssebulime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Omali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Mulindwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Laker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Waitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Andia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Hoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard S.","family":"Bagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari C.","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Therapy. 2014;3:83\u2013102.","journal-title":"Infect Dis Therapy"},{"issue":"9","key":"800_CR2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1093\/jac\/dkab159","volume":"76","author":"C Watera","year":"2021","unstructured":"Watera C, et al. HIV drug resistance among adults initiating antiretroviral therapy in Uganda. J Antimicrob Chemother. 2021;76(9):2407\u201314.","journal-title":"J Antimicrob Chemother"},{"key":"800_CR3","unstructured":"Organization WH. Transition to new antiretroviral drugs in HIV programmes: clinical and programmatic considerations, in Transition to new antiretroviral drugs in HIV programmes: clinical and programmatic considerations. 2017."},{"key":"800_CR4","unstructured":"Adoption WHP. Implementation status in countries. World Health Organization; 2019."},{"issue":"10143","key":"800_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0140-6736(18)31641-6","volume":"392","author":"E Nakkazi","year":"2018","unstructured":"Nakkazi E. Changes to dolutegravir policy in several African countries. Lancet. 2018;392(10143):199.","journal-title":"Lancet"},{"issue":"7","key":"800_CR6","first-page":"e461","volume":"7","author":"M Lamorde","year":"2020","unstructured":"Lamorde M, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. The lancet. HIV. 2020;7(7):e461\u20132.","journal-title":"HIV"},{"issue":"14","key":"800_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/09564624221129410","volume":"33","author":"D Namara","year":"2022","unstructured":"Namara D, et al. The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in kampala, uganda: A case-control study. Int J STD AIDS. 2022;33(14):1158\u201364.","journal-title":"Int J STD AIDS"},{"issue":"1","key":"800_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s41043-024-00695-0","volume":"43","author":"M Lartey","year":"2024","unstructured":"Lartey M, et al. Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in ghana: an observational longitudinal study. J Health Popul Nutr. 2024;43(1):199.","journal-title":"J Health Popul Nutr"},{"key":"800_CR9","doi-asserted-by":"crossref","unstructured":"Ankunda C, et al. Evaluating the glycemic effects of dolutegravir and its predictors among people with human immunodeficiency virus in uganda: A prospective cohort study. Open forum infectious diseases. Oxford University (Vol. 11, No. 10, p. ofae596); Press US; 2024.","DOI":"10.1093\/ofid\/ofae596"},{"issue":"Suppl 1","key":"800_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0213-005X(15)30002-1","volume":"33","author":"E Ribera","year":"2015","unstructured":"Ribera E, Podzamczer D. Mechanisms of action, Pharmacology and interactions of dolutegravir]. Enferm Infecc Microbiol Clin. 2015;33(Suppl 1):2\u20138.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"3\u20134","key":"800_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ceca.2011.11.006","volume":"51","author":"P Rorsman","year":"2012","unstructured":"Rorsman P, Braun M, Zhang Q. Regulation of calcium in pancreatic \u03b1-and \u03b2-cells in health and disease. Cell Calcium. 2012;51(3\u20134):300\u20138.","journal-title":"Cell Calcium"},{"issue":"5","key":"800_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-009-1314-y","volume":"52","author":"J-C Henquin","year":"2009","unstructured":"Henquin J-C. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia. 2009;52(5):739\u201351.","journal-title":"Diabetologia"},{"issue":"11","key":"800_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrendo.2013.166","volume":"9","author":"FM Ashcroft","year":"2013","unstructured":"Ashcroft FM, Rorsman P. KATP channels and islet hormone secretion: new insights and controversies. Nat Reviews Endocrinol. 2013;9(11):660\u20139.","journal-title":"Nat Reviews Endocrinol"},{"issue":"5209","key":"800_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1126\/science.7716547","volume":"268","author":"L Aguilar-Bryan","year":"1995","unstructured":"Aguilar-Bryan L, et al. Cloning of the \u03b2 cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423\u20136.","journal-title":"Science"},{"key":"800_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00125-003-1153-1","volume":"46","author":"P Rorsman","year":"2003","unstructured":"Rorsman P, Renstr\u00f6m E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46:1029\u201345.","journal-title":"Diabetologia"},{"issue":"1","key":"800_CR16","doi-asserted-by":"publisher","first-page":"30027","DOI":"10.1038\/srep30027","volume":"6","author":"R Yamanaka","year":"2016","unstructured":"Yamanaka R, et al. Mitochondrial Mg2\u2009+\u2009homeostasis decides cellular energy metabolism and vulnerability to stress. Sci Rep. 2016;6(1):30027.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"800_CR17","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndtplus\/sfr163","volume":"5","author":"W Jahnen-Dechent","year":"2012","unstructured":"Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i3\u201314.","journal-title":"Clin Kidney J"},{"key":"800_CR18","doi-asserted-by":"crossref","unstructured":"Maechler P et al. Role of mitochondria in \u03b2-cell function and dysfunction. Islets Langerhans, 2010 15:pp. 193\u2013216.","DOI":"10.1007\/978-90-481-3271-3_9"},{"issue":"2","key":"800_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1172\/JCI10582","volume":"106","author":"JE Pessin","year":"2000","unstructured":"Pessin JE, Saltiel AR. Signalling pathways in insulin action: molecular targets of insulin resistance. J Clin Investig. 2000;106(2):165\u20139.","journal-title":"J Clin Investig"},{"issue":"5651","key":"800_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1126\/science.1092952","volume":"302","author":"MF White","year":"2003","unstructured":"White MF. Insulin signalling in health and disease. Science. 2003;302(5651):1710\u20131.","journal-title":"Science"},{"issue":"5","key":"800_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2337\/diab.42.5.643","volume":"42","author":"MG Myers Jr","year":"1993","unstructured":"Myers MG Jr, White MF. The new elements of insulin signalling: insulin receptor substrate-1 and proteins with SH2 domains. Diabetes. 1993;42(5):643\u201350.","journal-title":"Diabetes"},{"issue":"3","key":"800_CR22","doi-asserted-by":"publisher","first-page":"E413","DOI":"10.1152\/ajpendo.00514.2001","volume":"283","author":"MF White","year":"2002","unstructured":"White MF. IRS proteins and the common path to diabetes. Am J Physiology-Endocrinology Metabolism. 2002;283(3):E413\u201322.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"3","key":"800_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1042\/bj3460561","volume":"346","author":"B Vanhaesebroeck","year":"2000","unstructured":"Vanhaesebroeck B, Alessi DR. The PI3K\u2013PDK1 connection: more than just a road to PKB. Biochem J. 2000;346(3):561\u201376.","journal-title":"Biochem J"},{"issue":"3","key":"800_CR24","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signalling: navigating the network. Cell. 2017;169(3):381\u2013405.","journal-title":"Cell"},{"issue":"9","key":"800_CR25","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/infdis\/jiac175","volume":"226","author":"I Jung","year":"2022","unstructured":"Jung I, et al. Dolutegravir suppresses thermogenesis via disrupting uncoupling protein 1 expression and mitochondrial function in brown\/beige adipocytes in preclinical models. J Infect Dis. 2022;226(9):1626\u201336.","journal-title":"J Infect Dis"},{"issue":"1","key":"800_CR26","doi-asserted-by":"publisher","first-page":"E108","DOI":"10.1152\/ajpendo.00471.2005","volume":"291","author":"R Krogh-Madsen","year":"2006","unstructured":"Krogh-Madsen R, et al. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab. 2006;291(1):E108\u201314.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"46","key":"800_CR27","doi-asserted-by":"publisher","first-page":"45777","DOI":"10.1074\/jbc.M301977200","volume":"278","author":"V Rotter","year":"2003","unstructured":"Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-\u03b1, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278(46):45777\u201384.","journal-title":"J Biol Chem"},{"issue":"2","key":"800_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.bbrc.2003.10.013","volume":"311","author":"C Lagathu","year":"2003","unstructured":"Lagathu C, et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by Rosiglitazone. Biochem Biophys Res Commun. 2003;311(2):372\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"800_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/met.2004.2.82","volume":"2","author":"JP Sutherland","year":"2004","unstructured":"Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2(2):82\u2013104.","journal-title":"Metab Syndr Relat Disord"},{"key":"800_CR30","doi-asserted-by":"crossref","unstructured":"Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Elsevier; 2004. pp. 228\u201332.","DOI":"10.1016\/S0939-4753(04)80048-6"},{"key":"800_CR31","doi-asserted-by":"crossref","unstructured":"Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int Med Case Rep J, 2021: pp. 503\u20137.","DOI":"10.2147\/IMCRJ.S323233"},{"key":"800_CR32","doi-asserted-by":"publisher","first-page":"2050313X2210794","DOI":"10.1177\/2050313X221079444","volume":"10","author":"AT Hirigo","year":"2022","unstructured":"Hirigo AT, et al. Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE Open Med Case Rep. 2022;10:2050313X221079444.","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"800_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jac\/dkx365","volume":"73","author":"M McLaughlin","year":"2018","unstructured":"McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73(1):258\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"800_CR34","first-page":"335","volume":"4","author":"M Gerschenson","year":"2001","unstructured":"Gerschenson M, et al. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult erythrocebus Patas monkeys. J Hum Virol. 2001;4(6):335\u201342.","journal-title":"J Hum Virol"},{"issue":"4","key":"800_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","volume":"102","author":"J-a Kim","year":"2008","unstructured":"Kim J-a, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circul Res. 2008;102(4):401\u201314.","journal-title":"Circul Res"},{"issue":"11","key":"800_CR36","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1097\/QAD.0000000000003278","volume":"36","author":"S Vakili","year":"2022","unstructured":"Vakili S, et al. Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy. AIDS. 2022;36(11):1493\u2013500.","journal-title":"AIDS"},{"issue":"10","key":"800_CR37","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","volume":"71","author":"J Gorwood","year":"2020","unstructured":"Gorwood J, et al. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020;71(10):e549\u201360.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"800_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3390\/biology12040580","volume":"12","author":"J Mohan","year":"2023","unstructured":"Mohan J, et al. Antiretrovirals promote metabolic syndrome through mitochondrial stress and dysfunction: an in vitro study. Biology. 2023;12(4):580.","journal-title":"Biology"},{"issue":"6","key":"800_CR39","doi-asserted-by":"publisher","first-page":"103583","DOI":"10.1016\/j.drudis.2023.103583","volume":"28","author":"Y Mishra","year":"2023","unstructured":"Mishra Y, Kaundal RK. Role of SIRT3 in mitochondrial biology and its therapeutic implications in neurodegenerative disorders. Drug Discovery Today. 2023;28(6):103583.","journal-title":"Drug Discovery Today"},{"key":"800_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1023\/A:1005400507802","volume":"31","author":"J Nedergaard","year":"1999","unstructured":"Nedergaard J, et al. UCP1: the original uncoupling protein\u2014and perhaps the only one? New perspectives on UCP1, UCP2, and UCP3 in the light of the bioenergetics of the UCP1-ablated mice. J Bioenerg Biomembr. 1999;31:475\u201391.","journal-title":"J Bioenerg Biomembr"},{"issue":"10","key":"800_CR41","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00157-11","volume":"55","author":"KE Hightower","year":"2011","unstructured":"Hightower KE, et al. Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"800_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jcph.439","volume":"55","author":"I Song","year":"2015","unstructured":"Song I, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"800_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.diabres.2014.04.006","volume":"105","author":"N Esser","year":"2014","unstructured":"Esser N, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141\u201350.","journal-title":"Diabetes Res Clin Pract"},{"key":"800_CR44","doi-asserted-by":"publisher","first-page":"120948","DOI":"10.1016\/j.lfs.2022.120948","volume":"308","author":"P Domingo","year":"2022","unstructured":"Domingo P, et al. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. Life Sci. 2022;308:120948.","journal-title":"Life Sci"},{"issue":"24","key":"800_CR45","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.3390\/molecules27249057","volume":"27","author":"AJ Theron","year":"2022","unstructured":"Theron AJ, et al. Pro-inflammatory interactions of dolutegravir with human neutrophils in an in vitro study. Molecules. 2022;27(24):9057.","journal-title":"Molecules"},{"issue":"1","key":"800_CR46","doi-asserted-by":"publisher","first-page":"e0226924","DOI":"10.1371\/journal.pone.0226924","volume":"15","author":"M Auclair","year":"2020","unstructured":"Auclair M, et al. HIV antiretroviral drugs, dolutegravir, Maraviroc and ritonavir-boosted Atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells. PLoS ONE. 2020;15(1):e0226924.","journal-title":"PLoS ONE"},{"issue":"3","key":"800_CR47","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/QAI.0000000000002861","volume":"89","author":"L Calza","year":"2022","unstructured":"Calza L, et al. Changes in serum inflammatory markers in antiretroviral therapy\u2013naive HIV-infected patients starting dolutegravir\/lamivudine or dolutegravir\/lamivudine\/abacavir. JAIDS J Acquir Immune Defic Syndr. 2022;89(3):e30.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"800_CR48","doi-asserted-by":"crossref","unstructured":"Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiological reviews; 2004.","DOI":"10.1152\/physrev.00015.2003"},{"issue":"3","key":"800_CR49","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmet.2014.07.005","volume":"20","author":"J Nedergaard","year":"2014","unstructured":"Nedergaard J, Cannon B. The Browning of white adipose tissue: some burning issues. Cell Metabol. 2014;20(3):396\u2013407.","journal-title":"Cell Metabol"},{"issue":"12","key":"800_CR50","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1194\/jlr.R700014-JLR200","volume":"48","author":"DL Brasaemle","year":"2007","unstructured":"Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res. 2007;48(12):2547\u201359.","journal-title":"J Lipid Res"},{"issue":"6","key":"800_CR51","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1172\/JCI46069","volume":"121","author":"AS Greenberg","year":"2011","unstructured":"Greenberg AS, et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Investig. 2011;121(6):2102\u201310.","journal-title":"J Clin Investig"},{"issue":"3","key":"800_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bcp.15177","volume":"88","author":"R Griesel","year":"2022","unstructured":"Griesel R, et al. Concentration\u2013response relationships of dolutegravir and Efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022;88(3):883\u201393.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"800_CR53","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","volume":"23","author":"SA Kliewer","year":"2002","unstructured":"Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687\u2013702.","journal-title":"Endocr Rev"},{"issue":"6","key":"800_CR54","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1073\/pnas.051551698","volume":"98","author":"JL Staudinger","year":"2001","unstructured":"Staudinger JL, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98(6):3369\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"800_CR55","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1172\/JCI26283","volume":"116","author":"C Zhou","year":"2006","unstructured":"Zhou C, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signalling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006;116(8):2280\u20139.","journal-title":"J Clin Invest"},{"issue":"1","key":"800_CR56","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","volume":"17","author":"H Yagura","year":"2017","unstructured":"Yagura H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"800_CR57","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FPC.0000000000000308","volume":"27","author":"K Tsuchiya","year":"2017","unstructured":"Tsuchiya K, et al. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017;27(11):416\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"800_CR58","doi-asserted-by":"crossref","unstructured":"Dabravolski SA et al. The role of mitochondrial mutations and chronic inflammation in diabetes. Int J Mol Sci, 2021. 22(13","DOI":"10.3390\/ijms22136733"},{"issue":"1","key":"800_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mito.2004.09.001","volume":"5","author":"LJ Guo","year":"2005","unstructured":"Guo LJ, et al. Mitochondrial genome polymorphisms associated with type-2 diabetes or obesity. Mitochondrion. 2005;5(1):15\u201333.","journal-title":"Mitochondrion"},{"issue":"3","key":"800_CR60","doi-asserted-by":"publisher","first-page":"e49612","DOI":"10.15252\/embr.201949612","volume":"21","author":"N Nissanka","year":"2020","unstructured":"Nissanka N, Moraes CT. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches. EMBO Rep. 2020;21(3):e49612.","journal-title":"EMBO Rep"},{"issue":"Pt 4","key":"800_CR61","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1469-1809.2005.00249.x","volume":"70","author":"D Crispim","year":"2006","unstructured":"Crispim D, et al. The European-specific mitochondrial cluster J\/T could confer an increased risk of insulin-resistance and type 2 diabetes: an analysis of the m.4216T\u2009>\u2009C and m.4917A\u2009>\u2009G variants. Ann Hum Genet. 2006;70(Pt 4):488\u201395.","journal-title":"Ann Hum Genet"},{"key":"800_CR62","doi-asserted-by":"crossref","unstructured":"Diaz-Morales N et al. Mitochondrial DNA haplogroup JT is related to impaired glycaemic control and renal function in type 2 diabetic patients. J Clin Med, 2018. 7(8)","DOI":"10.3390\/jcm7080220"},{"issue":"Supplement1","key":"800_CR63","first-page":"SUN","volume":"3","author":"P Kamal","year":"2019","unstructured":"Kamal P, Sharma S. SUN-187 dolutegravir causing diabetes. J Endocr Soc. 2019;3(Supplement1):SUN\u2013187.","journal-title":"J Endocr Soc"},{"issue":"8","key":"800_CR64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2174\/187152711799219271","volume":"10","author":"S Banu","year":"2011","unstructured":"Banu S, et al. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol Disorders-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disorders). 2011;10(8):921\u20137.","journal-title":"CNS Neurol Disorders-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disorders)"},{"key":"800_CR65","doi-asserted-by":"crossref","unstructured":"Mauvais-Jarvis F et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of \u03b2-cell dysfunction and insulin resistance. Diabetes. 2004. 53(3): pp. 645\u201353.","DOI":"10.2337\/diabetes.53.3.645"},{"issue":"3","key":"800_CR66","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2337\/diabetes.53.3.645","volume":"53","author":"F Mauvais-Jarvis","year":"2004","unstructured":"Mauvais-Jarvis F, et al. Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of \u03b2-cell dysfunction and insulin resistance. Diabetes. 2004;53(3):645\u201353.","journal-title":"Diabetes"},{"issue":"3","key":"800_CR67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/dme.13264","volume":"34","author":"E Lontchi-Yimagou","year":"2017","unstructured":"Lontchi-Yimagou E, et al. Ketosis\u2010prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes. Diabet Med. 2017;34(3):426\u201331.","journal-title":"Diabet Med"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00800-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:02:50Z","timestamp":1758884570000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00800-1","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}